Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Lybalvi
Published 2026-03-24 · Last reviewed 2026-03-31 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Maintains olanzapine’s antipsychotic efficacy with approximately 2–3 kg less weight gain versus olanzapine alone, yet metabolic monitoring remains standard.
FDA-approved (2021) for adult schizophrenia and bipolar I disorder (acute manic/mixed episodes and maintenance); brand-only tablets combine 5–20 mg olanzapine with 10 mg samidorphan.
Comparisons against other SGAs can be made in the compare view and the Lybalvi evidence feed can support review when addressing metabolic trade-offs or payer requests.
Often considered when olanzapine is clinically optimal but metabolic risk is high; payer authorization and structured metabolic counseling are common.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Olanzapine antagonizes dopamine D2/D3 and serotonin 5-HT2A/5-HT2C receptors, providing broad-spectrum antipsychotic and mood-stabilizing effects.
Samidorphan is a high-affinity µ-opioid antagonist (partial κ/δ activity) that dampens reward-driven appetite, mitigating olanzapine-related weight gain while maintaining psychiatric efficacy.
Olanzapine/samidorphan monitoring combines standard SGA metabolic safety with opioid-safety planning; the opioid contraindication is the defining risk that requires repeated reinforcement.